A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)

NCT07729956 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

436

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer (TNBC)

Interventions

DRUG: BL-B01D1
DRUG: PD-1 monoclonal antibody
DRUG: Nab-paclitaxel

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]